Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer

Nathan D. Seligson, Jill M. Kolesar, Benish Alam, Laura Baker, Jatinder K. Lamba, Brooke L. Fridley, Ameen A. Salahudeen, Daniel L. Hertz, J. Kevin Hicks

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Precision medicine has revolutionized clinical care for patients with cancer through the development of targeted therapy, identification of inherited cancer predisposition syndromes and the use of pharmacogenetics to optimize pharmacotherapy for anticancer drugs and supportive care medications. While germline (patient) and somatic (tumor) genomic testing have evolved separately, recent interest in paired germline/somatic testing has led to an increase in integrated genomic testing workflows. However, paired germline/somatic testing has generally lacked the incorporation of germline pharmacogenomics. Integrating pharmacogenomics into paired germline/somatic genomic testing would be an efficient method for increasing access to pharmacogenomic testing. In this perspective, the authors argue for the benefits of implementing a comprehensive approach integrating somatic and germline testing that is inclusive of pharmacogenomics in clinical practice. Tweetable abstract In this perspective, the authors argue that integrating pharmacogenomic testing into paired germline/somatic genomic testing would be an efficient method for increasing access to pharmacogenomic testing.

Original languageEnglish
Pages (from-to)731-738
Number of pages8
JournalPharmacogenomics
Volume24
Issue number13
DOIs
StatePublished - Aug 1 2023

Bibliographical note

Publisher Copyright:
© 2023 Future Medicine Ltd.

Keywords

  • PGx
  • adverse events
  • cancer
  • malignancy
  • precision medicine

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint

Dive into the research topics of 'Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer'. Together they form a unique fingerprint.

Cite this